Centers for Disease Control: estimated incidence of AIDS and deaths of person with AIDS, adjusted for delays in reporting, by quarter-year of diagnosis/death. United States. January 1985–June 1997.HIV/AIDS Surveill Rep. 1997;9:1–44.
Centers for Disease Control and Prevention. Update: trends in AIDS incidence, deaths and prevalence—United States, 1996.MMWR Morb Mortal Wkly Rep. 1997;46:165–173.
Montaner JSG, Reiss P, Cooper D, et al. for the INCAS Study Group. A randomized, double-blind trial comparing combination of nevaripine, didanosine, and zidovudine for HIV-infected patients.JAMA
Bangsberg D, Tulsky JP, Heicht RM, Moses AR. Protease inhibitors in the homeless.JAMA
Centers for Disease Control and Prevention. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.JAMA. 1993;269(10):2492.
Hoffman RA, Kung PC, Hansen WP, Goldstein G. Simple and rapid measurement of human T-lymphocytes and their subclasses in peripheral blood.Proc Natl Acad Sci USA
Giorgi JV, Cheng HL, Margolick JB, et al. Quality control in the flow cytometric measurement of T-lymphocyte subsets: the Multicenter AIDS Cohort experience.Clin Immunopathol. 1990;55:173–186.
Galai N, Vlahov D, Margolick JB, Graham N, Muñoz A. Changes in markers of disease progression in HIV-1 seroconverters: a comparison between cohorts of injecting drug users and homosexual men.J Acquir Immune Defic Syndr. 1995;8:66–74.
Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection.J Clin Microbiol.
Collier CA, Coombs RW, Schoenfeld DA, et al. for the AIDS Clinical Trial Group. Treatment of human immunodeficiency virus infection with saquinavir, zidivudine and zalcitabine.N Engl J Med.
Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.N Engl J Med.
Hammer SM, Squires KE, Hughes MD, et al. for the AIDS Clinical Trial Group 320 Study Team. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4+
cell counts of 200 per cubic millimeter or less.N Engl J Med.
Cameron DW, Heath-Chiozzi M, Cohen C, et al. for the Advanced HIV Disease Ritonavir Study Group. Randomized placebo-controlled trial of ritanovir in advanced HIV-1 disease.Lancet.
Piketty C, Castiel P, Belec L, et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease.AIDS
Casado JL, Perez-Elías MJ, Antela A, et al. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients.AIDS
d'Arminio Montforte A, Testa L, Adorni F, et al. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-infection.AIDS. 1998;12:1631–1637.
Mellors J. Combination protease inhibitor therapy. Session 84: update on antiretroviral therapy.Fourth Conference on Retroviruses and Opportunistic Infections; January 22–26, 1997; Washington, DC.
Deeks S, Beatty G, Cohen PT, Grant R, Volberding P. Viral load and CD4+ T cell changes in patients failing potent protease inhibitor therapy [abstract].Fifth Conference on Retroviruses and Opportunistic Infections; February 1–5, 1998; Chicago, IL.
Burger DM, Meenhorst PL, ten Napel CHH, et al. Pharmacokinetic variability of zidovudine in HIV-infected individuals: subgroup analysis and drug interactions.AIDS
Schwartz EL, Brechbühl A-B, Kahl P, Miller MA, Selwyn PA, Friedland GH. Pharmacokinetic interactions of zidovudine and methadone in intravenous drug—using patients with HIV infection.J Acquir Immune Defic Syndr.
McCance-Katz EF, Rainey P, Jatlow P, Friedland G. Methadone effects on zidovudine disposition (AIDS Clinical Trails Group 262).J Acquir Immune Defic Syndr. 1998;18:435–443.
Santolamazza M, Lelli V, Santollamazza M, et al. Evaluation of effectiveness of antiretroviral therapy in three groups of HIV+drug addicted patients [abstract].Int Conf AIDS. 1998;12:1159. Abstract 60868.
Veal GJ, Back DJ. Metabolism of zidovudine.Rev Gen Pharmacol. 1995;26:1469–1475.
D'Offizi G, Campitelli G, Urso R, et al. Methadone and protease inhibitors in HIV-infected drug users [abstract].Int Conf AIDS. 1998;12:782. Abstract 41202.
Flepp M, Nigg C, Kuhn F, et al. Nelfinaivr, didanosine and stavudine in HIV-infected drug users enrolled in opiate substitution programs at four outpatient clinic—the Zurich Prometheus Study [abstract].Int Conf AIDS. 1998;12:829. Abstract 42281.
Melvin DC, Lee JK, Belsey E, et al. The impact of co-infection with hepatitis C virus and human immunodeficiency virus on the tolerability of highly active antiretroviral therapy [abstract]. In:Program and Abstracts of the International Conference on the Discovery and Clinical Development of Antiretroviral Therapies; St. Thomas, West Indies; Antiviral Therapy 1998;3(suppl 5):56–57. Abstract 60.
Voorman RL, Maio SM, Hauer MJ, Sanders PE, Payne NA, Ackland MJ. Metabolism of delvaridine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYPD2D6 and CYP3A.Drug Metab Dispos
Koudriakova T, Iatsimirskaia E, Utkin I, et al. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir.Drug Metab Dispos
Fitzsimmons ME, Collins JM. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4.Drug Metab Dispos.
Payan C, Riou M, Dummont B, et al. Hepatitis B reactivation after triple combination therapy and higher immunological response for HIV-1 infection [abstract].Abstr Gen Meet Am Soc Microbiol. May 17–21, 1998;98:488. Abstract S-4.
Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V, Munoz F, Gonzalez-Lahoz J. Hepatotoxicity after introduction of highly active antiretroviral therapy (HAART) [abstract].Int Conf AIDS. 1998;12:70. Abstract 12288.
Vento S, Garofano T, Renzini C, Casali F, Ferraro T, Concia E. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy.AIDS
Jeurissen FJ, Schneider MM, Borleffs JC. Is the combination of hepatitis and indinavir potentially dangerous? [Letter].AIDS
Brau N, Leaf HL, Wieczorek RL, Margolis DM. Severe hepatitis in three AIDS patients treated with indinavir [letter; comment].Lancet
Arribas JR, Ibanez C, Ruiz-Antoran B, et al. Acute hepatitis in HIV-infected patients during ritonavir treatment [letter].AIDS
Coutinho RA. HIV and hepatitis C among injecting drug users. Success in preventing HIV has not been mirrored for hepatitis C.BMJ